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reSumo
Introdução: A cistatina C é considerada 
como um teste promissor para avaliar a 
taxa de filtração glomerular, pois apresenta 
características de um marcador endógeno 
ideal, sendo similar ou até superior à 
creatinina sérica, segundo alguns estudos. 
No entanto, é possível que alguns fatores 
(como corticoterapia) influenciem os níveis 
séricos da cistatina C, independente da 
taxa de filtração glomerular. Procurou-
se investigar se diferentes doses de 
glicocorticoides afetariam os níveis do 
marcador em pacientes com nefrite lúpica. 
Métodos: Foram avaliados 42 pacientes com 
nefrite lúpica, submetidos a 109 coletas de 
sangue diferentes; a idade média deles era 
de 37,7 ± 13,1 anos, e 88% eram do sexo 
feminino; a taxa de filtração glomerular 
estimada média era de 61,9 ± 20,0 mL/min. 
Os pacientes foram divididos, de acordo 
com a dose de corticoide, em dois grupos: A 
– altas (pulsoterapia com metilprednisolona 
e prednisona > 0,5 mg/kg/dia, n = 14) 
versus B – baixas doses (prednisona ≤ 0,5 
mg/kg/dia, n = 28). Os níveis de creatinina 
sérica foram usados como parâmetros de 
comparação em relação à função renal. A 
cistatina C foi determinada por metodologia 
desenvolvida in-house, usando citometria de 
fluxo na plataforma Luminex. Resultados: 
Considerando esses dois grupos, os níveis 
de cistatina C foram diferentes apenas nas 
amostras da segunda consulta (p = 0,106). 
Mas, quando considerados os níveis de 
creatinina sérica nos mesmos grupos, foi 
observada uma diferença marginalmente 
significante entre eles (p=0,070), sugerindo 
que a diferença nos níveis de cistatina C entre 
os grupos foi causada por suas respectivas 
taxas de filtração glomerular. Não houve 
diferença entre os que receberam, ou não, 
pulsoterapia. Conclusões: Embora alguns 
abStract
Introduction: Cystatin C is considered 
a promising test to evaluate glomerular 
filtration rate, since it has characteristics 
of an ideal endogenous marker, being 
similar or even superior to serum 
creatinine according to some studies. 
However, it is possible that some factors 
(as corticotherapy) could have an influence 
on serum cystatin C levels regardless of 
the glomerular filtration rate. The aim of 
this study was to investigate if different 
doses of glucocorticoid could have an 
influence on serum cystatin C levels in 
lupus nephritis patients. Methods: We 
evaluated 42 patients with lupus nephritis 
that performed 109 different blood 
collections; their mean age was 37.7 ± 
13.1 years old, and 88% were female; the 
mean estimated glomerular filtration rate 
was of 61.9 ± 20.0 mL/min. Patients were 
divided according to their glucocorticoid 
dose in two groups: A – high (pulse 
therapy with methylprednisolone and 
prednisone > 0.5 mg/kg/d, n = 14) versus 
B – low doses (prednisone ≤ 0.5 mg/kg/d, 
n = 28). Serum creatinine levels were 
used as parameters for renal function 
comparison. Cystatin C was determined 
by an in-house methodology, using 
Luminex system flow citometry. Results: 
Considering these groups, cystatin C levels 
were different only in the second visit (p 
= 0.106). But, when the serum creatinine 
levels were considered in the same groups, 
a marginally significant difference among 
them (p = 0.070) was observed, which 
suggested that the difference in cystatin 
C levels between the groups was caused 
by their respective glomerular filtration 
rate. There was not any difference 
between those groups that received or 
did not receive pulse therapy. Conclusion: 
Os níveis séricos de cistatina C sofrem infl uência da dose 
de corticoide em pacientes com nefrite lúpica?
Are serum cystatin C levels infl uenced by steroid doses in lupus 
nephritis patients?
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IntroductIon
There are many markers and methods to estimate 
renal function, and the gold standard used to 
determine glomerular filtration rate (GFR) is the 
measure of the clearances of exogenous substances, 
such as inulin, iohexol, Cr5¹-EDTA, Tc99-DTPA 
and I125-iothalamate.1 On the other hand, urea and 
creatinine serum (sCreat) levels are endogenous 
markers of renal function frequently used, but 
they present several limitations.1,2 The inexistence 
of an ideal index of renal function, which is easily 
applicable in daily practice, imposes the search for 
new substances.3 
Serum cystatin C (sCysC) has been proposed 
as a promising marker of the GFR and it is seen as 
equivalent or even superior to sCreat.4-6 However, 
it is not clear if other factors beyond renal function 
have an influence on sCysC levels. Initially, it was 
accepted there were not in vivo factors that could 
have interference on its levels.7 Nevertheless, since 
its clinical application was initiated, conditions that 
could interfere on its serum concentration beyond 
renal function were reported, as corticosteroid 
therapy, thyroid dysfunction, chronic liver disease, 
malignancies, organ transplantation, and many 
others.1,8-20 In addition, some authors consider the 
possibility that sCysC values could be increased in 
the event of male gender, increasing age, weight, and 
height. Moreover, its levels could be influenced by 
smoking, similarly to C-reactive protein, as a marker 
of inflammation and cardiovascular mortality.21-24
In fact, the superiority of sCysC over sCreat in 
the evaluation of GFR was demonstrated in some 
circumstances, but it is still questionable whether 
nonrenal factors could interfere on its levels, as the 
use of glucocorticoids.7-13
The aim of this study is to evaluate whether 
corticosteroids have an influence on sCysC levels. In 
order to test this hypothesis, we evaluated patients 
with lupus nephritis using different doses of PO and 
IV glucocorticoids.
SubjectS and methodS
Forty-two patients with systemic lupus erythematosus 
(SLE), which diagnosis was established by the presence 
of at least four criteria of angiotensin receptor 
antagonists (ARA),25 were enrolled, and 109 blood 
samples were collected. These patients were followed in 
the Glomerulopathy Section (Division of Nephrology) 
of Universidade Federal de São Paulo (UNIFESP). All of 
them had renal involvement during the course of SLE. 
Patients with a previous renal biopsy were classified 
according to the World Health Organization (WHO) 
Lupus Nephritis Classification.26 The study was approved 
by the Ethics Committee, and patients were included in 
the study after signing their informed consent.
All patients included in this study had already 
used corticosteroids during the course of SLE, and 
in this study doses were defined according to their 
clinical status and presence of lupus activity evidence, 
which was evaluated by the application of SLEDAI-
2K criteria.27,28 Patients were evaluated during 
approximately five months (range from three to ten 
months). Renal function was assessed in three different 
visits in order to have more information about the 
association between sCysC and corticosteroid use. 
At each visit, clinical history, physical examination, 
sCysC and routine laboratory exams were performed, 
as well as the determination of the laboratory items 
necessary to calculate the SLEDAI-2K.
The exclusion criteria corresponded to concurrent 
lymphoproliferative or autoimmune diseases (as 
rheumatoid arthritis, ankylosing spondylitis, and 
Crohn disease), chronic infectious diseases (as 
AIDS), active infections (as tuberculosis and viral 
hepatitis), pre-dialysis chronic kidney disease, renal 
transplantation, malignances, and nonlupus related 
glomerulopathies. Many therapies were used to 
control SLE and lupus nephritis manifestations, 
including: corticosteroids, azathioprine, cyclosporine, 
cyclophosphamide, and antimalarials. Statins, 
angiotensin converting enzyme inhibitors (ACEi) and 
ARA II were also frequently administered. In addition, 
Although some previous studies have shown that 
glucocorticoid has an influence on serum cystatin C 
levels, we have not observed such interference in the 
lupus nephritis patients submitted to corticotherapy.
Keywords: Glucocorticoids. Cystatin C. Creatinine. 
Glomerular filtration rate. Lupus nephritis.
estudos tenham mostrado que os glicorticoides podem 
influenciar os níveis de cistatina C, não foi observada tal 
interferência nesta população de pacientes com nefrite 
lúpica submetidos à corticoterapia.
Palavras-chave: Glicocorticoides. Cistatina C. 
Creatinina. Taxa de filtração glomerular. Nefrite 
lúpica. 
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no patient used nonsteroidal anti-inflammatory drugs 
(NSAID) during the follow-up period, in order to 
reduce nephrotoxicity risk.
Patients were divided into two groups, according 
to the current corticosteroid doses: high (pulse 
therapy with methylprenisolone and prednisone > 
0.5 mg/kg/day) versus low doses (prednisone ≤ 0.5 
mg/kg/day). The classification was based on the 
highest corticosteroid dose they received daily; the 
pulse therapy group was defined when this type of 
treatment was used regardless of the oral prednisone 
dose, since pulse therapy had been administered within 
the last three or four weeks before sample collection, 
exceptionally six weeks before (when, for any reason, 
the drugs infusion was postponed but the cycles of 
IV pulse therapy were not interrupted). sCreat levels 
were used as a reference to establish if sCysC levels 
could be attributed only to renal function variation. 
Cystatin C
SCysC was determined by an in-house developed 
assay, using an automated microsphere-based flow 
cytometric methodology (Luminex, Austin, TX).29 
Briefly, the technique was as follows: captured 
monoclonal antibody A3P3 was covalently coupled to 
microspheres (beads) according to the manufacturer’s 
instructions. For the assay, 50 μL (containing 3,000 
beads) were incubated with 50 μL of serum (samples 
and standards) diluted 1:20 in PBS-BSA, 1.0% in 
individual wells of a 96-well filter-bottom microtiter 
plate (Millipore – MABV 1210). After one hour of 
incubation at room temperature with agitation, the 
beads were washed with PBS-BSA at 0.5%, and 
biotinylated anti-Cystatin C (polyclonal antibody 
– DAKO) was added. This step was followed by 
incubation at room temperature for one hour and a 
new cycle of washings, and streptavidin-phycoerythrin 
(Molecular Probes USA) were added and incubated 
for 30 minutes. After washings, 100 μL of PBS-BSA 
at 1.0% were added and the plate was analyzed in 
Luminex. Results were expressed in mg/L, using as 
reference a standard curve with calibrators from the 
Cystatin C kit - PET by DAKO.
This in-house assay was validated in linearity 
range and precision. The results obtained using this 
noncommercial assay were comparable to those of the 
commercial assays, using the kits N Latex Cystatin 
C, Dade Behring (r2 = 0.884) and Cystatin C PETKit, 
Dako (r2 = 0.814). We have also determined GFR in 
healthy voluntary individuals using iohexol clearance 
and the sCysC in-house assay, and a good correlation 
coefficient was obtained between them (r2 = 0.821). As 
the CysC methodology was developed in-house, normal 
reference values were also determined by the authors 
of this article. There was not a difference between the 
means when compared gender (Student’s t-test, p = 
0.844). The range of CysC corresponded to 0.40 - 0.91 
mg/L, and the reference interval of normality (mean ± 
two standard deviations – SD) was 0.38 - 0.86 mg/L, 
similar to that observed in other studies.30,31
Creatinine 
sCreat was determined by an automated method, 
based on alkaline picrate reaction, using Hitachi 
912 – Roche, and the results were expressed as 
mg/dL. Estimated GFR (e-GFR) was determined 
by the simplified MDRD formula.32
statistiCal analysis
Continuous variables were presented as mean ± SD. 
For comparison among samples means, Student’s 
t-test, ANOVA or Kruskal-Wallis tests (followed by 
Tukey multiple comparison test) were performed. 
The association among renal function markers 
was evaluated by Pearson’s correlation test. It was 
considered significant p ≤ 0.05. The software Sigma 
Stat 2.0 was used for all analyses.
reSultS
Mean age of the patients was 37.1 ± 13.1 years old (18 – 
78); 37 (88%) of them were females; 67%, Caucasians; 
19%, mulattos; and 14%, Afro-descendents. Mean 
time of SLE diagnosis was 9.0 ± 6.5 years (0.1 - 26.0). 
Mean e-GFR was 61.9 ± 20.0 mL/min. The mean 
interval between sample collections was 5.4 ± 1.9 
Characteristics (n = 42) Range**
Age (years) 37.2 ± 13.1* [18 - 78]
Gender (Male/Female) 5/37
Race (Caucasian/ mullato/
Afro-Brazilian)
28/8/6
Hypertension 26
Diabetes mellitus 3
Tobacco use 1
Renal biopsy 
(class III/IV/V/VI)
03/18/11/01
Serum creatinine (mg/dL) 1.20 ± 0.62 * [0.70 – 4.30]
Serum Cystatin C (mg/L) 1.26 ± 0.78 * [0.45 – 4.86]
e-GFR (MDRD - mL/
min/1,73m2)
61.9 ± 20.0 * [11.4 – 101.0]
Table 1 DemographiC, laboratory, CliniCal, 
anD histologiCal CharaCteristiCs of 
patients
* Mean ± SD; ** if applicable.
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months for the three visits (Table 1). Patients that 
presented higher SLEDAI-2K score received (or had 
a tendency to receive) a higher dose of corticosteroid, 
when the four groups of doses (data not shown) were 
considered. Mean sCreat corresponded to 1.20 ± 0.62 
mg/dL and sCysC to 1.26 ± 0.78 mg/L. The correlation 
coefficients were: sCysC versus sCreat, r = 0.900,
1/sCreat versus e-GFR (MDRD), r = 0.949, 1/sCysC 
versus e-GFR (MDRD), r = 0.716.
When Groups A and B were analyzed, there was 
a statistically significant difference in the second 
visit, p = 0.035 (Table 2 and Figure 1). When sCreat 
levels were considered in order to evaluate eventual 
interference of renal function on these findings, it was 
still observed a tendency of a significant difference (p 
= 0.070). Therefore, it is possible that the alteration 
observed in sCysC levels was due to GFR deficit, 
instead of the use of medication.
When patients that have received pulse therapy 
with glucocorticoids versus those who have not were 
evaluated, regardless of the oral dose of prednisone, 
there was a tendency to observe an association 
between sCysC and glucocorticoid dose only in the 
first visit (p = 0.052), which was not seen in the 
following ones (second visit, p = 0.116; third visit, p 
= 0.522), as seen in Figure 2.
DisCUssion
Cystatin C is being considered as a potential candidate 
to replace serum creatinine in renal function evaluation, 
because it seems to be less affected by muscle mass.33 
However, recent reports have shown substantial 
variability in the relationship between GFR and sCysC 
among the populations evaluated, suggesting that there 
may be differences in generation, tubular reabsorption, 
or extra-renal elimination.2,34-35 Stevens et al. found a 
stronger association of sCreat rather than sCysC with 
surrogates of muscle mass, including age, sex, race, and 
urine creatinine.36 This reflects smaller contribution of 
muscle mass to generation of CysC than creatinine. 
Visits Serum levels Prednisone≤ 0.5 mg/kg/day Prednisone> 0.5 mg/kg/day and pulse therapy
(n = 28) (n = 14)
1st visit Creat 1.09 ± 0.59*     0.97** 1.22 ± 0.48*     1.06** p = 0.257
CysC 1.04 ± 0.62*     0.82** 1.42 ± 0.80*     1.10** p = 0.106
(n = 27) (n =10)
2nd visit Creat 1.20 ± 0.72*     1.10** 1.37 ± 0.43*     1.15** p = 0.070
CysC 1.24 ± 0.89*     1.00** 1.60 ± 0.66*     1.30** p = 0.035
(n = 25) (n =05)
3rd visit Creat 1.28 ± 0.72*     1.01** 1.00 ± 0.22*     1.00** p = 0.452
CysC 1.35 ± 0.88*     1.00** 1.01 ± 0.32*     0.93** p = 0.522
Table 2 leVels of sCreat anD sCysC aCCorDing to the groUps of patients that reCeiVeD higher anD 
loWer Doses of CortiCosteroiDs
* Mean ± SD, ** Median.
Figure 1. Comparison between the groups that received 
higher (pulse therapy and > 0.5 mg/kg/day) and lower 
doses (≤ 0.5 mg/kg/day) of corticosteroids.
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Figure 2. Comparison between patients that received 
or did not pulse therapy (independent of the oral 
prednisone dose).
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It is possible that GFR estimates, based on sCysC, 
are more accurate than estimates based on sCreat in 
patients with variation in creatinine generation due to 
diet or clinical conditions, which affect muscle mass, 
including chronic use of glucocorticoid.
In this study, we were not able to demonstrate 
any relation between corticosteroids and CysC levels 
in patients with lupus nephritis. In fact, initially, a 
difference between two groups was observed (patients 
that received ≤ 0.5 mg/kg versus pulse therapy in the 
first visit), but as renal function was evaluated based 
on sCreat levels at the same moment, a tendency 
to elevation of these values was documented, 
suggesting that increased levels of sCysC could be 
due to GFR decline. This was also observed when 
compared groups that received low and high doses 
of corticosteroid, and there was not a difference 
between those that used or did not pulse therapy. 
These data are in accordance with studies involving 
children with nephrotic syndrome, who received 
high doses of glucocorticoids, in which authors have 
not observed a correlation between sCysC levels and 
glucocorticoid use.22
On the other hand, Cimerman et al. observed an 
increase in CysC levels in patients with asthma, who 
had utilized metylprednisolone and oral glucocorticoid 
in comparison with those that had not used these 
drugs or received cyclosporine.12 Similarly, it was 
shown in patients using metylprednisolone due to 
severe subarachnoidal hemorrhage that sCysC levels 
were higher after seven days of treatment than at the 
time of admission in the hospital.37
Risch et al. showed that kidney transplant 
recipients on low-dose prednisone therapy had greater 
sCysC levels compared with those on steroid-free 
immunosuppressive therapy, but it was reported that 
the groups were not perfectly matched.10
Pöge et al. performed a paired analysis in which 
matching was based on GFR, sex, age, and weight 
in 20 kidney transplant recipients. They showed that 
patients receiving doses of prednisone higher than 10 
mg/day had more increased levels of sCysC than those 
using 5 mg/day.18 In a cross-sectional community based 
study, Wasen et al. found that glucocorticoid therapy 
was associated with higher sCysC levels, but they did 
not mention the dose of steroids.38 On the contrary, 
White et al. have not found such association.39
Rule et al. have shown that kidney transplant 
recipients had higher sCysC levels than patients with 
chronic kidney disease. This study used iothalamate 
clearance as gold standard.16 Le Bricon et al. have 
observed that sCysC has underestimated GFR in 
14%, three months after transplantation.40 Manetti 
et al. showed in Graves ophtalmopathy patients 
treated with high doses of methylprednisolone 
a significant increase of sCysC after 24 and 48 
h of medication use, but the levels of sCreat have 
also increased after 48 hours, therefore, it was 
supposed that such increase could be due to the 
GFR change.13 Discrepancies in these studies might 
be caused by lack of adjustment for kidney function 
using an accepted reference standard.
As previously mentioned, several reports have 
shown an association between steroid use and sCysC 
concentration. The absence of sCysC elevation 
associated with corticotherapy in our population of 
lupus nephritis patients could be explained, among 
other reasons, by their previous and concurrent use of 
glucocorticoids. We could speculate that the gene that 
codifies CysC was already activated by the induction 
of the promoter, determined by the previous use of the 
drug, and, consequently, there would not be current 
activation changes, neither alteration of sCysC levels. 
Bjarnadottir et al. have proposed this mechanism 
in their in vitro study, with HeLa cells. They have 
demonstrated that after 48 hours of dexamethasone 
use, a dose-dependent increase in sCysC levels 
occurred and this was attributed to the induction of 
the promoter mediated by glucocorticoids, increasing 
the transcription of the CysC gene.11 Such gene 
activation could be transitory and occur only during 
the use of such drugs.
It is noteworthy that the present study has some 
limitations, and the most important are: the small 
population and lack of a “gold standard” method 
to determine the GFR of this specific patient sample. 
It is also necessary to mention that thyroid function 
abnormalities are known to interfere in sCysC levels, 
which increase in hyperthyroidism and decrease in 
hypothyroidism.8,17 Multifactorial thyroid disorders 
are frequent in SLE patients, in which higher 
prevalence of hypothyroidism as well as of thyroid 
autoantibodies detection is widely described.41,42 
However, we did not have cases of thyroid disorders 
at the onset of this study, since we did not evaluate 
periodically the thyroid function of these patients.
This study adds evidence against an interference 
of steroids on sCysC levels, but further randomized 
studies are certainly necessary to evaluate this 
possible association to avoid misinterpretation of 
this GFR marker, in patients under treatment with 
glucocorticoids.
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